venetoclax
roche,abbvie
['cll', 'ave/']
dr. tausch from noted that ighv unmutated status and notch1 mut still independently assoc w/ inferior outcomes in pts w/ cll tx'ed w/ frontline ven-based regimens (along w/ mutated braf/ras, which was non-prognostic w/ frontline fcr/br). #ash22 #cllsm 
Leukemia/cell therapy doc & AYA Leukemia Program Leader at @MSKCancerCenter w/ special interest in ALL. Indie rock & Boston sports fan. Opinions=my own.??????